Neurology Advisor

NeurologyAdvisor.com provides healthcare professionals in the field of neurology with a rich source of practical information and resources to help them make informed choices for their patients. Key features include: - Brief summaries of medications - Daily news updates - In-depth feature articles - Exclusive case studies in neurology - Coverage of conferences - Useful clinical charts - Opportunities for continuing medical education (CME) - And much more...

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#1025372

United States

#386704

Health/Health Conditions and Concerns

#1116

Traffic sources

Monthly visitors

Articles

Eptinezumab Benefit for Chronic Migraine Linked to Patient-Reported Good Days

5 days ago | neurologyadvisor.com | Jessica Nye

An improvement of at least 75% in self-rated good days per month serves as a comprehensive and effective outcome for assessing antimigraine medication efficacy in chronic migraine, according to study results presented at the 2025 American Headache Society (AHS) Annual Scientific Meeting, held from June 19-22, in Minneapolis, Minnesota, and virtually. The traditional threshold for response to migraine treatment has been a 50% or greater reduction in average monthly migraine days.
Better Migraine Response With mMR vs Gepants in Phase 3 EMERGE Trial

5 days ago | neurologyadvisor.com | Jessica Nye

Meloxicam and rizatriptan (mMR) are associated with a better response to treatment than gepants among patients with migraine who have an inadequate response to gepants, according to study results presented at the 2025 American Headache Society (AHS) Annual Scientific Meeting, held from June 19-22, in Minneapolis, Minnesota, and virtually. Meloxicam is a nonsteroidal anti-inflammatory drug and rizatriptan is a selective serotonin receptor agonist.
CoQ10 May Support Symptom Resolution in Pediatric New Daily Persistent Headache

1 week ago | neurologyadvisor.com | Hibah Khaja

Coenzyme Q10 (CoQ10) supplementation is significantly associated with headache resolution in pediatric patients diagnosed with new daily persistent headache (NDPH), according to study results presented at the 2025 American Headache Society (AHS) Annual Scientific Meeting, held from June 19-22, in Minneapolis, Minnesota, and virtually.
Routine Neuroimaging Rarely Alters Diagnosis, Management in Pediatric Migraine

1 week ago | neurologyadvisor.com | Jessica Nye

Most pediatric patients with migraine have normal neuroimaging results, and among those with abnormal findings, none required medical intervention or changes to their migraine management. according to study results presented at the 2025 American Headache Society (AHS) Annual Scientific Meeting, held from June 19-22, in Minneapolis, Minnesota, and virtually. Among children and adolescents, migraine is the second most common primary headache disorder.
Fremanezumab Reduces Monthly Migraine Days in Children and Adolescents

1 week ago | neurologyadvisor.com | Jessica Nye

Fremanezumab is associated with a significant reduction in monthly migraine days among children and adolescents with episodic migraine, according to study results presented at the 2025 American Headache Society (AHS) Annual Scientific Meeting, held from June 19-22, in Minneapolis, Minnesota, and virtually. Fremanezumab is a humanized monoclonal antibody that is approved by the United States (US) Food and Drug Administration (FDA) for the treatment of migraine among adults.
Xifyrm Approved for Management of Moderate to Severe Pain

1 week ago | neurologyadvisor.com | Jaymin Kang

The Food and Drug Administration (FDA) has approved Xifyrm™ (meloxicam injection) for use in adults for the management of moderate to severe pain, alone or in combination with non-NSAID (non-steroidal anti-inflammatory) analgesics. Meloxicam, an NSAID, works by inhibiting cyclooxygenase 1 and 2, leading to analgesic, anti-inflammatory, and antipyretic effects.
Fremanezumab Reduces Migraine Days and Depressive Symptoms in Adults With MDD

1 week ago | neurologyadvisor.com | Hibah Khaja

In adult patients with migraine and comorbid major depressive disorder (MDD), treatment with fremanezumab is associated with significant reductions in both monthly migraine days (MMDs) and depressive symptoms, according to study results published in JAMA Neurology.
Intravenous Thrombolysis Improves Odds of Home Discharge in Ischemic Stroke

1 week ago | neurologyadvisor.com | Ron Goldberg

Likelihood of home discharge in cervical artery dissection–related acute ischemic stroke (CeAD-AIS) is improved with intravenous thrombolysis (IVT) without increasing risk for intracerebral hemorrhage or inpatient death, according to study findings published in the Journal of the American Heart Association. CeAD accounts for 10% to 20% of all strokes among young adults globally. Efficacy of IVT in CeAD-AIS is controversial.
Neurosteroids: A Novel Therapeutic Approach for Mood and Neurological Disorders

2 weeks ago | neurologyadvisor.com | Jessica Nye

Neurosteroids may have a therapeutic application in the management of mood and neurological disorders, according to results of a review presented at the American Psychiatric Association Annual Meeting, held virtually from May 17 to 21, 2025 in Los Angeles, California. Neurosteroids, such as brexanolone, ganaxalone, sepranolone, and zuranolone may have clinical application for managing mood and neurological disorders.
Drug-Device Combo Therapy Under Review for Parkinson Disease

2 weeks ago | neurologyadvisor.com | Diana Ernst

The Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for ND0612 for the treatment of motor fluctuations in patients with Parkinson disease. ND0612 is an investigational drug-device therapy that provides a 24-hour continuous subcutaneous infusion of levodopa/carbidopa solution.